Get the Stockscreener App
4.01
0.75%
0.03
After Hours:
4.09
0.08
+2.00%
Larimar Therapeutics Inc stock is traded at $4.01, with a volume of 1.13M.
It is up +0.75% in the last 24 hours and down -34.05% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$3.98
Open:
$3.95
24h Volume:
1.13M
Relative Volume:
1.30
Market Cap:
$255.86M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-4.3587
EPS:
-0.92
Net Cash Flow:
$-33.46M
1W Performance:
-35.01%
1M Performance:
-34.05%
6M Performance:
-47.17%
1Y Performance:
+4.43%
1-Day Range:
$3.87
$4.17
1-Week Range:
$3.01
$5.17
52-Week Range:
$3.01
$13.68
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.01 | 255.86M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
What is HC Wainwright’s Forecast for LRMR FY2025 Earnings? - Defense World
William Blair Has Negative Estimate for LRMR Q1 Earnings - Defense World
FY2025 Earnings Estimate for LRMR Issued By HC Wainwright - MarketBeat
William Blair Has Pessimistic Outlook of LRMR Q1 Earnings - MarketBeat
Charles Schwab Investment Management Inc. Lowers Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
Larimar Therapeutics announces initial data from OLE study of nomlabofusp - Yahoo Finance
Larimar Therapeutics (NASDAQ:LRMR) Given “Buy” Rating at HC Wainwright - Defense World
Why Is Larimar Therapeutics Stock Trading Lower On Monday? - AOL
Larimar Therapeutics' SWOT analysis: nomlabofusp's potential lifts stock outlook - Investing.com
Larimar Therapeutics' (LRMR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
LRMR Stock Hits 52-Week Low at $3.79 Amid Market Fluctuations - Investing.com Australia
LRMR Stock Hits 52-Week Low at $3.79 Amid Market Fluctuations By Investing.com - Investing.com South Africa
Larimar Therapeutics stock plunges on clinical study concerns By Investing.com - Investing.com Canada
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia - The Manila Times
Larimar Therapeutics Announces Positive Initial Data from - GlobeNewswire
Larimar's Nomlabofusp Shows Breakthrough Results in Friedreich's Ataxia Treatment, FXN Levels Surge 72% - StockTitan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Point72 Asset Management L.P. Sells 396,481 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
When (LRMR) Moves Investors should Listen - Stock Traders Daily
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MSN
Janus Henderson Group PLC Grows Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics's SWOT analysis: nomlabofusp progress lifts stock outlook By Investing.com - Investing.com Nigeria
Larimar Therapeutics's SWOT analysis: nomlabofusp progress lifts stock outlook - Investing.com India
Verition Fund Management LLC Decreases Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Fred Alger Management LLC Has $5.15 Million Stock Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN
Larimar Therapeutics (NASDAQ:LRMR) Given Outperform Rating at William Blair - MarketBeat
Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 - The Manila Times
Larimar Therapeutics Presents Additional Data from Phase 1 - GlobeNewswire
Larimar Reports Promising Clinical Data for Friedreich's Ataxia Treatment Nomlabofusp | LRMR Stock News - StockTitan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from Analysts - MarketBeat
Nomlabofusp shows promise in Friedreich's ataxia study - Investing.com
(LRMR) Trading Signals - Stock Traders Daily
Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Blue Owl Capital Holdings LP Increases Stake in Larimar Therapeu - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Janus Henderson's Strategic Acquisition in Larimar Therapeutics - GuruFocus.com
Verition Fund Management LLC Reduces Stake in Larimar Therapeuti - GuruFocus.com
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
Goldman Sachs Group Inc's Strategic Acquisition in Larimar Thera - GuruFocus.com
Research Analysts Offer Predictions for LRMR FY2024 Earnings - Defense World
What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat
Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com
Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Larimar Therapeutics Inc Stock (LRMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flynn James E | Director |
Feb 16 '24 |
Buy |
8.74 |
4,290,617 |
37,499,993 |
6,151,406 |
| THOMAS FRANK E | Director |
Feb 14 '24 |
Buy |
11.00 |
2,000 |
22,000 |
2,000 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):